Holen Sie sich die Stockscreener-App
9.93
0.73%
-0.04
Schlusskurs vom Vortag:
$9.97
Offen:
$9.98
24-Stunden-Volumen:
86,855
Relative Volume:
0.09
Marktkapitalisierung:
$640.93M
Einnahmen:
$202.09M
Nettoeinkommen (Verlust:
$-61.69M
KGV:
-9.1944
EPS:
-1.08
Netto-Cashflow:
$-35.64M
1W Leistung:
+0.89%
1M Leistung:
-18.07%
6M Leistung:
-24.45%
1J Leistung:
-23.92%
1-Tages-Spanne:
$9.745
$9.98
1-Wochen-Bereich:
$8.75
$10.06
52-Wochen-Spanne:
$8.67
$17.82
Evolus Inc Stock (EOLS) Company Profile
Firmenname
Evolus Inc
Sektor
Telefon
(949) 284-4555
Adresse
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
Vergleichen Sie EOLS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
9.94 | 632.51M | 202.09M | -61.69M | -35.64M | -1.08 |
|
HLN
Haleon Plc Adr
|
11.18 | 50.54B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
170.91 | 74.02B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.8368 | 4.22M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.99 | 45.82B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.34 | 20.31B | 16.54B | -1.64B | 749.00M | -1.45 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-17 | Eingeleitet | BTIG Research | Buy |
| 2024-01-29 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-06-23 | Eingeleitet | Needham | Buy |
| 2022-05-12 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-01-20 | Hochstufung | Truist | Hold → Buy |
| 2021-05-06 | Hochstufung | Mizuho | Neutral → Buy |
| 2021-04-08 | Bestätigt | H.C. Wainwright | Buy |
| 2021-02-24 | Herabstufung | Truist | Buy → Hold |
| 2020-07-07 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-02-06 | Fortgesetzt | Mizuho | Buy |
| 2019-11-26 | Eingeleitet | SVB Leerink | Outperform |
| 2019-09-05 | Fortgesetzt | Mizuho | Buy |
| 2019-06-28 | Eingeleitet | Wells Fargo | Market Perform |
| 2019-06-11 | Eingeleitet | Barclays | Underweight |
| 2019-03-20 | Eingeleitet | SunTrust | Buy |
| 2019-02-14 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-01-29 | Eingeleitet | Stifel | Buy |
Alle ansehen
Evolus Inc Aktie (EOLS) Neueste Nachrichten
Evolus Launches Second Product Line for Wrinkles - Orange County Business Journal
Evolus boosts balance sheet with lower-cost refinancing and flexibility - MSN
Evolus announces CFO resignation - MSN
Stifel maintains Evolus stock buy rating, $25 target - Investing.com Australia
Midday Stock Roundup: Activist Investor Targets El Pollo Loco - Orange County Business Journal
Stifel maintains Evolus stock buy rating, $25 target By Investing.com - Investing.com Nigeria
Increases to CEO Compensation Might Be Put On Hold For Now at Evolus, Inc. (NASDAQ:EOLS) - simplywall.st
Mizuho maintains Evolus stock Outperform rating and $25 target By Investing.com - Investing.com India
Evolus CFO Sandra Beaver resigns for new role By Investing.com - Investing.com South Africa
Mizuho maintains Evolus stock Outperform rating and $25 target - Investing.com
Evolus CFO to Resign - Orange County Business Journal
Evolus CFO Sandra Beaver Resigns - marketscreener.com
Evolus (EOLS) CFO Resignation Announced - GuruFocus
Evolus CFO Sandra Beaver Announces Resignation - TipRanks
Resignation of CFO Impacts Evolus (EOLS) Leadership | EOLS Stock News - GuruFocus
Evolus Announces Departure of its Chief Financial Officer | EOLS Stock News - GuruFocus
Evolus announces departure of CFO Sandra Beaver - TipRanks
Evolus CFO Sandra Beaver resigns for new role - Investing.com
Evolus Announces Departure Of Its Chief Financial Officer - marketscreener.com
Evolus Announces Departure of its Chief Financial Officer - Business Wire
Evolysse HA gels outperform Restylane in clinical study - Investing.com Australia
Evolus Announces Publication of U.S. Pivotal Study for Evolysse Form and Evolysse Smooth Injectable Hyaluronic Acid Gels - marketscreener.com
Evolus announces publication of U.S. pivotal study for Evolysse injectable gels - TipRanks
EOLS Publishes Promising Study Results on Evolysse Injectable Gels | EOLS Stock News - GuruFocus
Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels - BioSpace
Evolysse HA gels outperform Restylane in clinical study By Investing.com - Investing.com Canada
Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ - GuruFocus
Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels | EOLS Stock News - GuruFocus
Trend Tracker for (EOLS) - news.stocktradersdaily.com
Deutsche Bank AG Cuts Stock Holdings in Evolus, Inc. (NASDAQ:EOLS) - Defense World
Comerica Bank Purchases New Stake in Evolus, Inc. (NASDAQ:EOLS) - Defense World
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to 16 newly hired non-executive employees - BioSpace
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | EOLS Stock News - GuruFocus
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Evolus Executives Sell Shares to Cover Tax Obligations - TradingView
Evolus, Inc. (NASDAQ:EOLS) Shares Sold by Voya Investment Management LLC - Defense World
Evolus, Inc. (EOLS): A Bull Case Theory - Insider Monkey
Evolus (NASDAQ:EOLS) Earns Buy Rating from Needham & Company LLC - Defense World
Evolus projects $345M-$355M revenue for 2025 with new product launches - MSN
Analyst Estimates: Here's What Brokers Think Of Evolus, Inc. (NASDAQ:EOLS) After Its First-Quarter Report - simplywall.st
Evolus, Inc. (NASDAQ:EOLS) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - Yahoo
Analysts Offer Insights on Healthcare Companies: Evolus (EOLS) and Arcus Biosciences (RCUS) - The Globe and Mail
Evolus, Inc. Reports Strong Q1 Growth Amid Challenges - TipRanks
EOLS Stock: Needham Reiterates Buy Rating with $22 Target | EOLS Stock News - GuruFocus
Evolus, Inc. (NASDAQ:EOLS) Q1 2025 Earnings Call Transcript - Insider Monkey
What Analysts Are Saying About Evolus Stock - Benzinga
Evolus Inc (EOLS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Market Challenges - Yahoo Finance
Evolus Inc (EOLS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Market Challenges By GuruFocus - Investing.com Canada
Evolus, Inc. Reports Strong Q1 2025 Growth - TipRanks
Earnings call transcript: Evolus Q1 2025 results miss forecasts, stock rises - Investing.com Nigeria
Finanzdaten der Evolus Inc-Aktie (EOLS)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.28%
2.99%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):